Jpmorgan Chase & CO Chemomab Therapeutics Ltd. Put Options Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding CMMB
# of Institutions
16Shares Held
2.66MCall Options Held
0Put Options Held
0-
Orbimed Advisors LLC San Diego, CA2.24MShares$2.2 Million0.04% of portfolio
-
Ikarian Capital, LLC Dallas, TX213KShares$209,1240.02% of portfolio
-
Two Sigma Investments, LP New York, NY40KShares$39,1940.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny37.8KShares$37,0440.0% of portfolio
-
Kestra Private Wealth Services, LLC31.2KShares$30,6160.0% of portfolio
About Chemomab Therapeutics Ltd.
- Ticker CMMB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,431,700
- Market Cap $11.2M
- Description
- Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (...